Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress.

Chapman CM, Sun X, Roschewski M, Aue G, Farooqui M, Stennett L, Gibellini F, Arthur D, Pérez-Galán P, Wiestner A.

Clin Cancer Res. 2012 Apr 1;18(7):1979-91. doi: 10.1158/1078-0432.CCR-11-2113. Epub 2012 Feb 20.

2.

PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL).

Okkenhaug K, Burger JA.

Curr Top Microbiol Immunol. 2016;393:123-42. doi: 10.1007/82_2015_484. Review.

3.

TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia.

Bresin A, D'Abundo L, Narducci MG, Fiorenza MT, Croce CM, Negrini M, Russo G.

Cell Death Dis. 2016 Jan 28;7:e2071. doi: 10.1038/cddis.2015.419. Review.

4.

Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.

Vangapandu HV, Jain N, Gandhi V.

Expert Opin Investig Drugs. 2017 May;26(5):625-632. doi: 10.1080/13543784.2017.1312338. Epub 2017 Apr 13. Review.

PMID:
28388280
5.

Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.

Fan AC, O'Rourke JJ, Praharaj DR, Felsher DW.

Expert Opin Investig Drugs. 2013 Nov;22(11):1495-509. doi: 10.1517/13543784.2013.829453. Epub 2013 Aug 12. Review.

6.

The biology behind PI3K inhibition in chronic lymphocytic leukaemia.

Ortiz-Maldonado V, García-Morillo M, Delgado J.

Ther Adv Hematol. 2015 Feb;6(1):25-36. doi: 10.1177/2040620714561581. Review.

Supplemental Content

Support Center